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A B S T R A C T   
Aims: Using the UK Biobank cohort, a large sample of middle aged and older adults in the UK, the present study 
aimed to examine the cross-sectional association between type 2 diabetes and cognition and to assess the 
hypothesised mediating role of common comorbid conditions, whilst controlling for important demographic and 
lifestyle factors. 
Methods: Using regression models and general structural equation models, we examined the cross-sectional as-
sociation between type 2 diabetes status and: fluid intelligence; reaction time; visual memory; digit span and 
prospective memory; and the hypothesised mediating role of common comorbid conditions: visceral obesity; 
sleep problems; macrovascular problems; respiratory problems; cancer and depressive symptoms in 47,468 
participants from the UK Biobank cohort, of whom 1,831 have type 2 diabetes. We controlled for ethnicity, sex, 
age, deprivation, smoking status, alcohol consumption, physical activity levels and use of diabetes medication. 
Results: Participants with type 2 diabetes had a significantly shorter digit span, b = -0.14, CIs [-0.27, -0.11] than 
those without type 2 diabetes. Those with type 2 diabetes did not differ from those without type 2 diabetes on 
fluid intelligence, reaction time, visual memory and prospective memory. The associations that do exist between 
type 2 diabetes and cognition are consistently mediated via macrovascular problems, depressive symptoms, and 
to a lesser extent visceral obesity. Respiratory problems, sleep disturbances and cancer did not mediate the 
association between type 2 diabetes status and measures of cognition. 
Conclusions: Comorbid conditions explain some of the observed association between type 2 diabetes and 
cognitive deficits. This suggests that prevention, management or treatment of these comorbid conditions may be 
important to reduce the likelihood of cognitive decline. Treatment studies with long follow-ups are needed to 
examine this.   
1. Introduction 
Cross-sectional and longitudinal research has shown that type 2 
diabetes is associated with cognitive deficits (Strachan et al., 1997; van 
den Berg et al., 2009). A review of cognitive deficits in people with type 
2 diabetes found that the most common deficits were in the areas of 
processing speed (found in 63% of studies), attention (50% of studies), 
memory (44%), cognitive flexibility (38%), language (33%), general 
intelligence (31%), and perception and construction (22%) (van den 
Berg et al., 2009). Few studies have examined the underlying 
mechanisms. One possibility is that common comorbidities found in 
those with type 2 diabetes explain the association between type 2 dia-
betes and cognitive deficits. 
People with type 2 diabetes may suffer more frequently from visceral 
obesity (Russell-Jones and Khan, 2007) sleep disturbances (Resnick 
et al., 2003), macrovascular complications (coronary artery disease, 
stroke, peripheral vascular disease) (Cade, 2008; Stratton, 2000), res-
piratory problems (Tiengo et al., 2008), and some cancers (Giovannucci 
et al., 2010). Further, type 2 diabetes has been associated with depres-
sion and depressive symptoms (Lloyd et al., 2018; Pouwer et al., 2020). 
Abbreviations: SEM, structural equation model; MET, metabolic equivalent; CRP, C-reactive protein; HbA1c, glycated haemoglobin. 
* Corresponding author. Present address: Cancer Intelligence, Cancer Research UK, 2 Redman Place, London, E20 1JQ, United Kingdom. 
E-mail address: f.rutters@amsterdamumc.nl (F. Rutters).  
Contents lists available at ScienceDirect 
Psychoneuroendocrinology 
journal homepage: www.elsevier.com/locate/psyneuen 
https://doi.org/10.1016/j.psyneuen.2020.104902 
Received 22 January 2020; Received in revised form 22 September 2020; Accepted 22 September 2020   
Psychoneuroendocrinology 123 (2021) 104902
2
Many of these comorbidities have also been associated with cogni-
tive impairments independently of diabetes. First, visceral obesity, 
assessed by waist circumference has been associated with impairments 
in executive function, perception, construction, memory and processing 
speed (Higgs and Spetter, 2018; Prickett et al., 2015; Smith et al., 2011; 
van den Berg et al., 2009). Second, sleeping disturbances have been 
associated with impairments in response speed and attentional pro-
cessing (Killgore, 2010). Third, 25–30% of ischemic stroke survivors 
develop immediate or delayed vascular cognitive impairments or 
vascular dementia (Kalaria et al., 2016). Fourth, cognitive deficits are 
common in people with obstructive lung diseases, such as chronic 
obstructive pulmonary disease and asthma (Dodd, 2015). Fifth, cogni-
tive deficits have been well documented in patients with cancer, both 
before and after treatment has started (Pendergrass et al., 2018). Finally, 
with regard to depression, pronounced deficits have been found in ex-
ecutive function, working memory, attention and psychomotor pro-
cessing speed in those with major depression (McIntyre et al., 2013). 
Given the associations observed in the literature, we hypothesised 
that the comorbidities of type 2 diabetes mediate the association be-
tween type 2 diabetes and cognition. See Fig. 1 for a conceptual model of 
the hypothesised associations between type 2 diabetes, comorbidities 
and cognition. To date, this hypothesis has not been tested. Some pre-
vious studies did, however, control for comorbidities in attempt to 
isolate the effect of type 2 diabetes on cognition (Fuh et al., 2007; van 
den Berg et al., 2009). The results from these studies were mixed, with 
some studies showing that comorbidities were not a confounder (van 
den Berg et al., 2009), while another did show confounding by the 
comorbidities (Fuh et al., 2007). For example, one study showed that 
depressive symptoms had additive effects on cognitive decline above 
and beyond the effect of type 2 diabetes (Demakakos et al., 2017). 
However, no research to date has examined whether the association 
between type 2 diabetes and cognition is mediated by the 
above-mentioned comorbidities in one comprehensive study. 
Using the UK Biobank cohort, a large sample of middle aged and 
older adults in the UK, the present study examined the cross-sectional 
association between type 2 diabetes and cognition, and assessed the 
hypothesised mediating role of common comorbid conditions, whilst 
controlling for important demographic and lifestyle factors. 
2. Method 
2.1. Participants and design 
The UK Biobank consists of baseline data collected from 503,325 
adults aged 40-69 years recruited via NHS registers across England, 
Scotland and Wales between 2006 and 2010 (Allen et al., 2012). Par-
ticipants completed a single 2-3 hour testing session where they first 
provided written consent, and then completed touch screen question-
naires (measuring lifestyle, environment and medical history), cognitive 
tasks and face-to-face interviews. Lastly, physical measures and bio-
logical samples were taken. Several enhancements were conducted 
during this time period, where subsets of participants completed more 
detailed assessments to calibrate the data collected at baseline e.g. 
mailed tri-axial accelerometers to supplement physical activity ques-
tionnaire data. For more detail on how the data was collected see Allen 
and colleagues (2012). The UK Biobank intend to conduct follow-up 
assessments where baseline measurements are repeated on subsets of 
20-25,000 participants every 2-3 years. One follow-up assessment has 
been conducted so far on 20,436 participants in 2012-2013. This 
follow-up assessment utilised a more restricted battery of cognitive as-
sessments, and in a relatively small sample size, therefore the current 
study utilised only data collected at baseline. 
2.2. Ethics 
This research is covered by the Research Tissue Bank approval ob-
tained by the UK Biobank. The UK Biobank was approved by the North 

































Fig. 1. Model of type 2 diabetes status as a predictor of cognition, mediated by type 2 diabetes comorbidities. Panel a shows path c, panel b shows paths a, b, c’. 
Note. The first subscript in the figure refers to the mediator (M), the second subscript refers to the outcome (Y). 
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approved by Middlesex University’s Psychology Research Ethics Sub- 
Committee. 
2.3. Measures 
2.3.1. Identification of type 2 diabetes 
Participants self-reported a Doctor’s diagnosis of diabetes. Partici-
pants were excluded if they reported being prescribed insulin within one 
year of diagnosis or were diagnosed before they were 35 years of age. 
This was done in an attempt to exclude those who likely had type 1 
diabetes and maintain only those with type 2 diabetes. Participants who 
self-reported as having gestational diabetes and who did not report their 
age of diagnosis were excluded from the study. 
Glycated haemoglobin (HbA1c) levels are provided to describe the 
sample. Blood samples were analysed using the High Performance 
Liquid Chromatography (HPLC) method in a Bio-Rad Variant II Turbo 
analyser. 
2.3.2. Cognition 
Five tasks were used to assess a range of cognitive abilities. These 
tasks have been shown to be a valid measure of general cognitive 
functioning (Lyall et al., 2016). 
2.3.3. Fluid intelligence test 
This task assessed a person’s ability to solve problems that require 
logic and reasoning, but that is independent of acquired knowledge 
(Kane and Engle, 2002). Participants answered as many questions as 
possible (out of 13) in 2 minutes. The total number of correct answers 
was the outcome measure (fluid intelligence score). 
2.3.4. Reaction time task 
Participants were shown 12 pairs of cards (4 practice, 8 experi-
mental) on the screen and pressed a button when the cards were iden-
tical. This task assessed simple processing speed (Karia et al., 2012). 
Mean time taken to press the button on trials where the cards matched 
was the outcome measure (mean reaction time). 
2.3.5. Pairs memory test 
This was a paired associates learning task where participants were 
shown an array of cards on screen and were asked to remember as many 
matching pairs as possible. The cards were then turned over to be face 
down and participants touched as many matching pairs as possible with 
the fewest attempts. Paired associate learning tasks have been validated 
as a measure of new learning and memory (Tulsky and Price, 2003; 
Wechsler, 1997, 1987). The outcome measure was the number of 
incorrect matches found on the highest level (level 6). A greater number 
of incorrect matches suggests poorer visual memory as participants were 
less able to remember where the correct matching pair locations were. 
This task is referred to as the visual memory task (errors) from here on. 
2.3.6. Numeric memory test 
In this task participants were shown a sequence of numbers on the 
screen and, after a 3000 ms blank screen, had to enter the sequence in 
the correct order using the keyboard. Task difficulty increased by one 
digit after each correct answer (up to 12) and ended after two consec-
utive incorrect answers. This is a forwards digit span task and is a 
validated measure of phonological loop short-term memory store ca-
pacity (Baddeley et al., 1998). The maximum sequence length correctly 
recalled was the outcome measure (digit span). 
2.3.7. Prospective memory test 
At the beginning of the cognitive assessments participants read the 
following instruction on screen “At the end of the games, we will show 
you four coloured shapes and ask you to touch the Blue Square. How-
ever, to test your memory, we want you to actually touch the Orange 
Circle instead”. As the final cognition task participants were shown a 
number of shapes on the screen and were asked to touch the blue square, 
as they were told they would be. Outcome measures were the number of 
people that correctly touched the orange circle on the first attempt and 
on the second attempt (creating a dichotomous outcome of incorrect vs 
correct). We subsequently refer to these outcomes as ‘prospective 
memory first attempt’ and ‘prospective memory second attempt’. This 
task assessed an individual’s ability to remember an instruction and 
recall it at a later time following a cue (McDaniel and Scullin, 2010). 
2.3.8. Hypothesised mediators 
Visceral obesity was measured using waist circumference, which was 
determined at the level of the umbilicus by a trained member of staff. 
Participants who self-reported insomnia “usually” or narcolepsy “often/ 
all of the time” were coded as having a sleep disturbance (dichotomous 
variable, no vs yes). Participants were coded as having macrovascular 
problems if they self-reported a diagnosis of angina, high blood pressure, 
blood clot, lung clot, deep vein thrombosis, or previous heart attack or 
stroke (dichotomous variable, no vs yes). Participants were coded as 
having respiratory problems if they self-reported a diagnosis of 
emphysema/chronic bronchitis, asthma, or hay fever/allergic rhinitis/ 
eczema (dichotomous variable, no vs yes). A lifetime cancer diagnosis 
was also self-reported (dichotomous variable, no vs yes). Depressive 
symptoms were assessed using four questions from the Patient Health 
Questionnaire (PHQ-9, Spitzer et al., 1999). These asked “over the past 
two weeks, how often have you… (1) felt down, depressed or hopeless, 
(2) had little interest or pleasure in doing things, (3) felt tense, fidgety or 
restless, (4) felt tired or had little energy?” Answers were scored in line 
with PHQ-9 scoring guidelines to create a total depressive symptoms 
score, where a higher score indicates more symptoms (Spitzer et al., 
1999). 
2.3.9. Confounders 
Participants self-reported their ethnicity, sex and age. Ethnicity was 
recoded as white vs non-white. Townsend deprivation index score was 
used as a proxy measure of socioeconomic status (Townsend et al., 
1988). The score reflects material deprivation, and is based on infor-
mation about unemployment, housing, access to a car and social class. 
Higher scores indicate greater deprivation. Smoking status and alcohol 
consumption were self-reported (never, previous or current), and reco-
ded into dichotomous variables (never vs previous/current). Physical 
activity was measured via the International Physical Activity Ques-
tionnaire (Craig et al., 2003). Data processing guidelines were followed 
to calculate total MET (metabolic equivalent of task) minutes across 
walking, moderate and vigorous physical activity (IPAQ, 2005). Spe-
cifically, where the sum of walking, moderate and vigorous activity 
minutes was greater than 960 minutes (indicating implausible levels of 
physical activity), these values were treated as missing data (N = 682). 
Use of diabetes medication (dichotomous, yes vs no) was also included 
as a potential confounder. 
2.4. Analysis strategy 
Data analyses were conducted in SPSS and STATA. Missing data for 
confounders were imputed using the sample mean. First, the total effect 
(c paths in Fig. 1) of type 2 diabetes status on cognition were examined 
using linear regression for continuous outcomes (fluid intelligence score, 
mean reaction time, visual memory task errors, digit span) and logistic 
regression for dichotomous outcomes (prospective memory first 
attempt, prospective memory second attempt). To assess whether co-
morbid health problems mediate the association between type 2 dia-
betes status and cognition, we ran a generalised structural equation 
model (SEM) for each outcome with diabetes status as the predictor 
variable (X; no type 2 diabetes vs type 2 diabetes), cognition outcomes as 
the dependent variables (Y: fluid intelligence score, mean reaction time, 
visual memory task errors, digit span, prospective memory first attempt, 
prospective memory second attempt) and comorbidities as the mediator 
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variables (M: visceral obesity, sleep disturbances, macrovascular prob-
lems, respiratory problems, cancer, depressive symptoms). SEM models 
were adjusted for demographic and lifestyle factors known to be asso-
ciated with cognition, including ethnicity, age, sex, deprivation, phys-
ical activity MET minutes, and smoking and alcohol consumption by 
entering these as covariates. Use of diabetes medication was also 
included as a covariate. Covariates were mean centered. We report the 
effect of type 2 diabetes status on the hypothesised mediator variables (a 
paths), the effect of the hypothesised mediator variables on cognition (b 
paths), and the direct effect of type 2 diabetes status on cognition (c’ 
paths). We also report the indirect effect of type 2 diabetes status on 
cognition via hypothesised mediators (paths a*b). We consider the six 
measures of cognition to be a family of tests and have therefore applied a 
Bonferroni correction of 0.05/6 (p < 0.008, with 99.2% confidence in-
tervals) to the c and c’ pathways. We do not consider the six mediators to 
be a family of tests, and so interpret the a pathways as significant if 
p < 0.05. The b and axb pathways for each mediator are tested six times 
(once for each of the six measures of cognition). A Bonferroni correction 
has therefore been applied to the b and axb pathways and these are 
interpreted as significant if p < 0.008 (0.05/6, with 99.2% confidence 
intervals). Bootstrapped confidence intervals (1,000 resamples) were 
estimated for the indirect effects. Proportion mediated was used as a 
summary measure of the mediation analyses (indirect effect divided by 
total effect) (MacKinnon et al., 2007). See Fig. 1 for a conceptual model 
of the association between variables. 
3. Results 
3.1. Sample 
Only participants who self-reported type 2 diabetes status and had 
valid responses on all measures of cognition and planned mediator 
variables were included in the current analyses. The analysed sample 
consisted of 47,468 persons, of whom 1,831 (3.9%) had type 2 diabetes. 
There was missing data for some confounding variables: physical ac-
tivity MET minutes (n = 10,120), smoking status (n = 131), deprivation 
score (n = 117) and alcohol consumption (n = 24), which were imputed 
using their mean value. See Table 1 for characteristics of the sample. 
Participants with type 2 diabetes had a slightly higher age, higher per-
centage of men, higher percentage of white ethnicity and greater 
deprivation than those without type 2 diabetes. Participants with type 2 
diabetes reported doing less physical activity and were more likely to be 
previous/current smokers, but were less likely to be previous/current 
alcohol drinkers than those without diabetes. The type 2 diabetes group 
had a higher prevalence of visceral obesity, sleep disturbances, macro-
vascular problems, cancer diagnoses and a greater number of depressive 
symptoms, but were slightly less likely to have respiratory problems 
than those without type 2 diabetes. Participants with type 2 diabetes had 
a much higher average HbA1c. 
See Fig. 2 for a graphical representation of significant model paths. 
3.2. Total effects (c paths) 
Participants with type 2 diabetes had a significantly shorter digit 
span compared to controls. Those with type 2 diabetes did not signifi-
cantly differ from controls on fluid intelligence score, mean reaction 
time, errors on the visual memory task, and performance on the first and 
second attempt of the prospective memory task (Table 2). 
3.3. Effect of type 2 diabetes status on hypothesised mediators (a paths) 
Having type 2 diabetes was significantly associated with greater 
visceral obesity, the presence of sleep disturbances and macrovascular 
problems, and a greater number of depressive symptoms, but not with 
respiratory problems or a cancer diagnosis (Table 3). Specifically, 
compared to controls, people with type 2 diabetes had a 9.09 cm greater 
waist circumference (visceral obesity), had a 0.07 times increased risk of 
having sleep disturbances, had a 0.34 times increased risk of having 
macrovascular problems, and had 0.37 more depressive symptoms. 
3.4. Effect of hypothesised mediators on cognition (b paths) 
A short summary of the results is provided for all comorbidities. For 
the complete results, see Table 3. 
3.4.1. Visceral obesity 
Greater visceral obesity was significantly associated with shorter 
digit span and fewer errors on the visual memory task, but was not 
significantly associated with any other measures of cognition. 
3.4.2. Sleep disturbances 
The presence of sleep disturbances was not significantly associated 
with any measures of cognition. 
3.4.3. Macrovascular problems 
The presence of macrovascular health problems was significantly 
associated with shorter digit span, lower fluid intelligence score, longer 
mean reaction time, more errors on the visual memory task and being 
less likely to give the correct response first time on the prospective 
memory task. The presence of macrovascular health problems was not 
significantly associated with performance on the second attempt of the 
prospective memory task. 
3.4.4. Respiratory problems 
The presence of respiratory problems was significantly associated 
with a longer digit span, higher fluid intelligence score, and being more 
likely to give the correct answer on the first attempt of the prospective 
memory task. The presence of respiratory problems was not significantly 
associated with performance on any other measure of cognition. 
Table 1 
Sample characteristics as a function of type 2 diabetes status.   
Controls 










Age (years) 56.29 8.27 60.75 6.31 
Sex (men) 44.6%  65.5%  
Ethnicity (white) 96.7%  91.1%  
Townsend deprivation indexa − 1.61 2.72 − 0.86 2.95 
Physical activity (MET 
minutes) 
3183.97 3195.56 2832.13 2787.82 
Smoking (previous/current) 44.6%  57.6%  
Alcohol consumption 
(previous/current) 
96.5%  93.6%  
HbA1c (mmol/mol)b 35.24 4.37 52.37 13.14 
Length of diabetes (years)   6.12 5.37 
Diabetes medication (yes) 0.1%  61.9%  
Visceral obesity (cm) 88.85 12.94 103.63 13.77 
Sleep disturbances (yes) 29.5%  38.8%  
Macrovascular problems (yes) 28.9%  72.4%  
Respiratory problems (yes) 30.4%  28.7%  
Cancer diagnosis (yes) 7.7%  9.1%  
Depressive symptomsc 1.53 2.00 1.92 2.35 
Digit span (number of items) 6.73 1.32 6.46 1.41 
Visual memory task (errors) 3.98 3.10 4.30 3.35 
Fluid intelligence scored 6.09 2.08 5.79 2.19 
Reaction time (ms) 562.54 120.11 590.48 126.43 
Prospective memory 1st 
attempt (correct) 
78.6%  71.4%  
Prospective memory 2nd 
attempt (correct) 
17.4%  20.9%  
Note. aHigher scores indicate greater deprivation; bHbA1c = glycated haemo-
globin, data missing for 2431 participants; cpossible symptom score range of 0- 
12; dpossible score range of 0-13. T2D = type 2 diabetes. 
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3.4.5. Cancer 
Having a cancer diagnosis was not significantly associated with any 
measures of cognition. 
3.4.6. Depressive symptoms 
A higher number of depressive symptoms was associated with a 
shorter digit span, lower fluid intelligence score, longer mean reaction 
time, more errors on the visual memory task, and being less likely to give 
the correct answer on the first attempt of the prospective memory task 
and more likely to give the correct answer on the second attempt. 
3.4.7. Indirect effect of type 2 diabetes status on cognition via hypothesised 
mediators (a x b paths) 
The indirect effects of type 2 diabetes status on digit span, fluid in-
telligence, mean reaction time, visual memory task errors, first attempt 
on the prospective memory task via an increase in macrovascular 
problems and depressive symptoms were significant (Table 3). The ef-
fect of type 2 diabetes status on the second attempt on the prospective 
memory task was significantly mediated via an increase in depressive 
symptoms alone. Macrovascular problems mediated 14-59% of the as-
sociation between type 2 diabetes status and the different cognitive 
outcomes, and depressive symptoms mediated 10%-48% of these asso-
ciations. The effect of diabetes status on digit span and visual memory 
via an increase in visceral obesity was also significant, with visceral 
obesity mediating 31-49% of the association for digit span. Respiratory 
problems, sleep problems and cancer did not mediate the association 
between type 2 diabetes status and any measures of cognition. 
3.5. Direct effects (c’ path) 
The association between type 2 diabetes status and digit span was 
reduced and no longer significant when the effect of hypothesised me-
diators was removed (Table 3). 
4. Discussion 
Using the UK Biobank cohort, a large sample of middle aged and 
older adults in the UK, the present study aimed to examine the cross- 
sectional association between type 2 diabetes and cognition and to 
assess the hypothesised mediating role of common comorbid conditions, 
whilst controlling for important demographic and lifestyle factors. In 
this cohort, people with type 2 diabetes significantly differed from 
controls on one aspect of cognition, namely short term memory, but not 
on intelligence, processing speed, new learning and memory. These 
findings are in line with previous reviews that have found inconsistent 
associations between type 2 diabetes and areas of cognition across 
studies. For example, in a review van den Berg and colleagues (2009) the 
most consistent cognitive deficit found in type 2 diabetes (processing 


































Fig. 2. Model of type 2 diabetes status as a predictor of cognition, mediated by type 2 diabetes comorbidities. Panel a shows path c, panel b shows paths a, b, c’. 
Significant pathways highlighted green/represented by thick lines. 
Note. The first subscript in the figure refers to the mediator (M), the second subscript refers to the outcome (Y). 
Table 2 
Summary of (unstandardised) total effect (c path) of type 2 diabetes status on 
measures of cognition, adjusted for confounders (ethnicity, sex, age, deprivation 
score, smoking status, alcohol consumption, physical activity, diabetes medi-
cation) (N = 47,468).  






Digit span (number of items) − 0.14 − 0.27 − 0.11 
Fluid intelligence scorea − 0.16 − 0.36 0.04 
Mean reaction time (ms) 4.95 − 6.41 16.30 
Visual memory task (errors) − 0.13 − 0.44 0.17 
Prospective memory 1st attempt 
(yes vs no) 
− 0.04 − 0.27 0.19 
Prospective memory 2nd attempt 
(yes vs no) 
− 0.04 − 0.29 0.22 
Note. apossible score range of 0-13. T2D = type 2 diabetes. 
V. Whitelock et al.                                                                                                                                                                                                                              
Psychoneuroendocrinology 123 (2021) 104902
6
Table 3 
Summary of mediator models (unstandardized effects) between type 2 diabetes status (IV) and cognition (DV) via comorbid health conditions (M), controlling for 

































9.09* 8.25 9.93 − 0.005* − 0.01 − 0.003 − 0.07 − 0.19 0.06 − 0.04* − 0.06 − 0.03 
Sleep 
disturbances 
(yes vs no)  
0.07* 0.03 0.10 − 0.001 − 0.04 0.04    − 0.00004 − 0.003 0.002 
Macrovascular 
problems (yes 
vs no)  
0.34* 0.30 0.38 − 0.06* − 0.09 − 0.02    − 0.02* − 0.03 − 0.01 
Respiratory 
problems (yes 
vs no)  
0.01 − 0.03 0.04 0.07* 0.03 0.10    0.0004 − 0.003 0.004 
Cancer (yes vs 
no)  
0.001 − 0.01 0.02 0.02 − 0.04 0.08    0.00001 − 0.001 0.001 
Depressive 
symptomsa  





scoreb    
− 0.002 − 0.004 0.001 − 0.06 − 0.26 0.14 − 0.01 − 0.04 0.01 
Sleep 
disturbances 
(yes vs no)     
− 0.02 − 0.08 0.03    − 0.002 − 0.01 0.003 
Macrovascular 
problems (yes 
vs no)     
− 0.19* − 0.25 − 0.14    − 0.07* − 0.09 − 0.04 
Respiratory 
problems (yes 
vs no)     
0.18* 0.12 0.23    0.001 − 0.01 0.01 
Cancer (yes vs 
no)     
− 0.02 − 0.11 0.07    − 0.00002 − 0.002 0.001 
Depressive 
symptomsa     




time (ms)    
− 0.02 − 0.15 0.10 2.37 − 9.06 13.79 − 0.18 − 1.39 1.00 
Sleep 
disturbances 
(yes vs no)     
− 1.51 − 4.66 1.64    − 0.10 − 0.36 0.14 
Macrovascular 
problems (yes 
vs no)     
6.33* 3.09 9.58    2.15* 1.04 3.34 
Respiratory 
problems (yes 
vs no)     
− 1.38 − 4.41 1.65    − 0.01 − 0.14 0.08 
Cancer (yes vs 
no)     
− 2.81 − 8.02 2.41    − 0.002 − 0.11 0.10 
Depressive 
symptomsa     




task (errors)    
− 0.01 − 0.01 − 0.004 − 0.13 − 0.43 0.18 − 0.06 − 0.10 − 0.03 
Sleep 
disturbances 
(yes vs no)     
− 0.07 − 0.15 0.02    − 0.005 − 0.01 0.001 
Macrovascular 
problems (yes 
vs no)     
0.12* 0.03 0.21    0.04* 0.01 0.07 
Respiratory 
problems (yes 
vs no)     
− 0.01 − 0.10 0.07    − 0.0001 − 0.003 0.002 
Cancer (yes vs 
no)     
− 0.01 − 0.15 0.13    − 0.00001 − 0.002 0.001 
Depressive 
symptomsa     





attempt)    
− 0.001 − 0.004 0.002 0.01 − 0.22 0.24 − 0.01 − 0.03 0.01 
Sleep 
disturbances 
(yes vs no)     
0.04 − 0.03 0.11    0.003 − 0.002 0.01     
− 0.08* − 0.14 − 0.01    − 0.03* − 0.05 − 0.003 
(continued on next page) 
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recent review concluded that an important measure of diabetes, namely 
HbA1c levels, only showed a weak negative association with cognitive 
function, which accounted for less than 10% of the variation in cognition 
(Geijselaers et al., 2015). Further, in the current study, across all mea-
sures of cognition, differences between those with and without type 2 
diabetes were small, compared to previous research. Participants with 
type 2 diabetes remembered 0.14 items less than controls on the digit 
span task (short-term memory). A previous study found a difference of 
1.3 items between those with and without type 2 diabetes (Fuh et al., 
2007). Similarly, in our study we found that participants with type 2 
diabetes had a reaction time 4.95 ms slower than those without diabetes, 
yet other studies have found significant differences in reaction time of 
~100 ms and more (Muhil et al., 2014; Priya, 2016; Richerson et al., 
2005). One possible explanation for the small effects observed in this 
study is that participants with type 2 diabetes may have had well 
controlled diabetes (average HbA1c on the day of testing was 
52 mmol/mol), which may have prevented large effects on cognition. 
Further, participants may not have had type 2 diabetes for long enough 
to observe a large effect on cognition. However, neither of these ex-
planations seem likely considering the widespread existence of comor-
bid conditions in this sample. Alternatively, it is possible that at a 
population level the size of the effects of diabetes on cognition are small, 
in contrast to previous studies that have found larger effects in smaller 
sample sizes. Finally, the UK Biobank cohort has been found to have 
healthier lifestyles and fewer self-reported health problems than the 
general UK population (Fry et al., 2017), which may have reduced the 
size of any effects in this sample. 
In this sample, people with type 2 diabetes had greater visceral 
obesity (waist circumference), were more likely to have macrovascular 
problems and sleep disturbances, and had a greater number of depres-
sive symptoms. The size of most of these effects was clinically relevant, 
except for the increased chance of sleep disturbances, which was small 
(0.07). These effects are consistent with other research findings (Cade, 
2008; Holt et al., 2014; Resnick et al., 2003; Russell-Jones and Khan, 
2007). 
The association between type 2 diabetes and cognitive performance 
was consistently mediated by the above mentioned macrovascular 
problems, depressive symptoms, and to a lesser extent visceral obesity. 
The indirect effect through these comorbidities explained a substantial 
proportion of the association between type 2 diabetes and cognition 
(specifically digit span, fluid intelligence, reaction time, prospective 
memory and visual memory; 10-59% mediation). This is in line with 
literature finding effects of these health problems on cognition (Kalaria 
et al., 2016; McIntyre et al., 2013; Smith et al., 2011; van den Berg et al., 
2009), and suggests that effects of type 2 diabetes on cognition may at 
least be partially caused by the comorbidities of type 2 diabetes. 
In some models inconsistent mediation was observed. In other 
words, the direct and indirect effect had opposite signs, cancelling each 
other out and resulting in a total effect close to zero (MacKinnon et al., 
2000). Specifically, in our models with visual memory and performance 
on the 1st and 2nd attempt of the prospective memory task as the 
dependent variables, non-significant negative direct effects combined 
with significant positive indirect effects cancelled out some total effects. 
Regardless of the inconsistency of the mediation model, the associations 
between type 2 diabetes and visual memory and prospective memory 1st 
attempt performance were mediated by depressive symptoms and 
macrovascular symptoms. The association between type 2 diabetes and 
prospective memory 2nd attempt performance was mediated by 
depressive symptoms only. The pattern of these effects is in line with the 
pattern of mediation described in the preceding paragraphs, i.e. signif-
icant mediators were macrovascular problems and depressive symp-
toms. These results show that an absence of a significant total effect does 
not imply that there is no mechanism behind the effect of type 2 diabetes 
on cognition, and that it is important to look past the total effect to gain a 
more detailed insight into the mechanism behind type 2 diabetes and 
cognition. 
There were also significant indirect effects in mediation models in 
which direct and indirect effects had the same sign. Specifically, the 
presence of macrovascular problems and depressive symptoms mediated 
the association between type 2 diabetes status and mean reaction time, 

































vs no)     
0.08* 0.01 0.15    0.0004 − 0.004 0.01 
Cancer (yes vs 
no)     
0.05 − 0.06 0.16    0.00004 − 0.002 0.002 
Depressive 
symptomsa     






attempt)    
0.0001 − 0.003 0.003 − 0.07 − 0.33 0.19 0.001 − 0.02 0.03 
Sleep 
disturbances 
(yes vs no)     
− 0.05 − 0.12 0.02    − 0.003 − 0.01 0.002 
Macrovascular 
problems (yes 
vs no)     
0.06 − 0.01 0.13    0.02 − 0.01 0.05 
Respiratory 
problems (yes 
vs no)     
− 0.06 − 0.13 0.02    − 0.0003 − 0.004 0.003 
Cancer (yes vs 
no)     
− 0.04 − 0.16 0.08    − 0.00003 − 0.002 0.002 
Depressive 
symptomsa     
0.05* 0.03 0.06    0.02* 0.01 0.03 
Note. T2D = type 2 diabetes; apossible symptom score range of 0-12; bpossible score range of 0-13. 
V. Whitelock et al.                                                                                                                                                                                                                              
Psychoneuroendocrinology 123 (2021) 104902
8
yet the direct and indirect effects were positive. Again, these effects 
follow the same pattern as the previous results, i.e. macrovascular 
problems and depressive symptoms were significant mediators. Further, 
visceral obesity significantly mediated the association between type 2 
diabetes status and errors on the visual memory task, however the direct 
and indirect effects were negative. 
Visceral obesity, macrovascular problems and depressive symptoms 
may affect cognition via several pathways. One possible pathway that is 
common to all three comorbidities is inflammation (Gorelick, 2010; 
McIntyre et al., 2013; Nguyen et al., 2014; Sullivan et al., 2000). In 
obesity, adipose hypertrophied adipocytes and resident immunes cells 
increase levels of proinflammatory cytokines, such as C-reactive protein 
(CPR) and interleukins (Nguyen et al., 2014). Major depression has been 
associated with pro-inflammatory markers, where those with greater 
symptom severity show higher levels of these markers (Raison et al., 
2006). A prospective longitudinal study found that depression was 
associated with later CRP levels, but CRP levels were not associated with 
later depression status, suggesting that depression caused the inflam-
mation (Copeland et al., 2012). In addition, inflammation is implicated 
in the development and progression of several types of vascular disease 
(Sullivan et al., 2000). Other pathways could include oxidative stress in 
depression (McIntyre et al., 2013) and disruption of the blood brain 
barrier in obesity (Nguyen et al., 2014). Future research should examine 
possible common underlying mechanisms for the mediating effects 
found in the current study. 
Some counterintuitive results that deserve consideration are the as-
sociations between the presence of respiratory problems and longer digit 
span, higher fluid intelligence score and being more likely to give the 
correct answer on the first attempt of the prospective memory task. This 
is contrary to research finding that respiratory problems are associated 
with cognitive deficits (Dodd, 2015). One possible explanation is the 
inclusion of allergy conditions in the categorisation of respiratory 
problems, which may have obscured effects of other respiratory prob-
lems on cognition. Histamine (the body’s natural response to allergens 
in the brain) aids concentration and learning. However, symptomatic 
allergies are typically associated with cognitive impairments (Church 
et al., 2016). It is therefore unlikely that the inclusion of allergy-based 
conditions with respiratory problems contributed to the counterintui-
tive findings. The consistent pattern of better cognition in those with 
respiratory problems found in the current study requires further 
investigation. 
Strengths and limitations 
A strength of the current study is the large sample size that provided 
sufficient power to detect small effects. The UK Biobank is one of the 
most comprehensive databases, containing extensive data on partici-
pants’ lifestyles, environment, medical history and physical measures in 
men and women aged 40 to 69 years. Consequently, we were able to 
control for a greater number of potentially confounding variables than 
has been controlled for before and examined a large number of 
hypothesised mediators. Further, the UK Biobank cognitive assessments 
have been shown to be a valid measure of general cognitive functioning 
(Lyall et al., 2016). Finally, we conducted parallel multiple mediation 
analysis, which allowed us to control for the effects of other mediators 
and therefore gives a more accurate picture of the indirect effect through 
each mediator independently of others (MacKinnon, 2008). 
There are also limitations to this study. As this is cross-sectional data, 
no strong causal inferences can be made. Indeed, reverse causality and 
bidirectional relationships between type 2 diabetes and the mediators 
tested are plausible. For example, depression and type 2 diabetes are risk 
factors for each other (Mezuk et al., 2008) as well as macro- and 
micro-vascular diabetes complications (Nouwen et al., 2019). As the UK 
Biobank continues to follow up participants, future work can examine 
the longitudinal mediating role of common comorbidities in the asso-
ciation between type 2 diabetes and cognitive deficits. All behaviour and 
diagnoses were self-reported and may be subject to underreporting or 
misreporting. Indeed, this may be the case for physical activity where 
many participants had implausible values. Similarly, self-reported 
diagnosis of cancer included everyone with a current diagnosis and 
survivors. This is important as cognitive deficits in cancer can vary by 
time since diagnosis/treatment (Harrington et al., 2010). In attempt to 
exclude those with type 1 diabetes, we excluded those prescribed insulin 
within 1 year of diagnosis or diagnosed under 35 years of age. Whilst this 
likely excluded all people with type 1 diabetes, it may have excluded 
some with early onset type 2 diabetes. There are other potential medi-
ators that might be of interest to future researchers. For example, other 
diabetes comorbidities, such as renal dysfunction and retinopathy are 
also associated with cognitive deficits and likely play a mediating role 
(Crosby-Nwaobi et al., 2012; Khatri et al., 2009). There are also several 
aspects of cognition previously found to be impaired in people with type 
2 diabetes that were not measured by the UK Biobank, such as cognitive 
flexibility and attention (van den Berg et al., 2009). Therefore, nothing 
can be said about the potential mediating role of health comorbidities in 
these cognitive domains. Finally, the UK Biobank cohort has been shown 
to have healthier lifestyles and fewer self-reported health conditions 
than the general population (Fry et al., 2017), which may have limited 
our ability to identify associations in this study. Our results may there-
fore not be representative of the general population. More specifically, 
our results may underestimate the mediating role of comorbid condi-
tions in the association between type 2 diabetes and cognition in the 
general population. 
4.1. Conclusions 
Comorbid conditions explain some of the observed association be-
tween type 2 diabetes and cognitive deficits. This suggests that pre-
vention, management or treatment of these comorbid conditions may be 
important to reduce the likelihood of cognitive decline. Treatment 
studies with long follow-ups are needed to examine this. 
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